Podcasts about antibodies

Immune system protein

  • 1,445PODCASTS
  • 2,698EPISODES
  • 36mAVG DURATION
  • 5WEEKLY NEW EPISODES
  • Oct 2, 2022LATEST
antibodies

POPULARITY

20152016201720182019202020212022

Categories



Best podcasts about antibodies

Show all podcasts related to antibodies

Latest podcast episodes about antibodies

This Week in Virology
TWiV 942: Omicron boosters with Paul Offit

This Week in Virology

Play Episode Listen Later Oct 2, 2022 113:54


Paul Offit returns to TWiV for a discussion of SARS-CoV-2 bivalent boosters containing ancestral and Omicron spike mRNAs, including their composition, why they are being recommended by CDC, and who would benefit the most from them. Hosts: Vincent Racaniello, Dickson Despommier, Rich Condit,  Kathy Spindler, and Brianne Barker Guest: Paul Offit Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Research assistant position at FDA (pdf) Support MicrobeTV with a Spike t-shirt (Vaccinated.us) CDC oversells bivalent booster (Wall St Journal) FDA authorizes bivalent COVID-19 booster Timestamps by Jolene. Thanks! Weekly Picks Dickson – Jazz favorites: Small group #4: Gerry Mulligan Quartet with Chet Baker: Gerry Mulligan, Baritone saxophone; Carson Smith, Bass; Larry Bunker, Drums, Chet Baker, Trumpet. Signature album: The Best Of The Gerry Mulligan Quartet With Chet Baker: Signature song: My Funny Valentine. Second pick: Wonder: Childhood and the Lifelong love of Science. Frank C. Keil. Brianne – A Devious Cellular Trick Cancers Can Use to Escape Your Immune System Kathy – Durable antimicrobial coating Rich – One Health Vincent – The works of Dashiell Hammett Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv

Metabolic Moments - Live better longer
Metabolic Moments: New Cancer Antibodies – And Made to Order?

Metabolic Moments - Live better longer

Play Episode Listen Later Sep 28, 2022 2:35


New cancer antibodies are being developed that connect cancer cells to immune killer cells. Learn from Dr. Power what makes a bi-specific cell and they can help you. Get in the know and listen to the show!

What The Folklore?
Episode 346: You Also Hear the Bush Yelling About UTIs, Right?

What The Folklore?

Play Episode Listen Later Sep 27, 2022 78:44


This week on WTFolklore, we're joined by a talking sweet potato to help us read through Godmother Death, but we do take some side roads to talk about Google's "feeling lucky" button, and how to best christen a new sketchbook. Oh, and lube. Lots and lots of lube.Thanks to Jayson for joining us this week!Suggested talking points: The Robin Hood of Antibodies, WAP (Wealth And Prosperity), Wrong As Rain, An Embarrassment of Vaults, The Non-est Profit, The Scent Of Your SoulIf you'd like to support Carman's artistic endeavors, visit: https://www.patreon.com/carmandaartsthingsIf you like our show, find us online to help spread the word! Follow us on Twitter, Facebook, and Youtube. Support us on Patreon to help the show grow at www.patreon.com/wtfolklore. You can find merchandise and information about the show at www.wtfolklorepodcast.com.

Coffee & Compatibility
The road to best practices in anti-HLA antibody testing

Coffee & Compatibility

Play Episode Listen Later Sep 26, 2022 35:24


HLA Innovators Dr. Robert Liwski, Dr. Annette Jackson and Dr. Anne Halpin set the stage for best practices in anti-HLA antibody testing and analysis on this special Coffee & Compatibility Episode. You do not want to miss this episode or the related session at this year's ASHI annual meeting in Las Vegas, NV October 24-28.

PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast
Sonia Glennie, ARNP, MSN, OCN, AGPCNP-BC - Moving Beyond Conventional Care for DLBCL: Oncology Nurse Leadership for the Effective and Safe Use of Innovative Antibody and Cellular Therapies

PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast

Play Episode Listen Later Sep 22, 2022 35:09


Go online to PeerView.com/ZUH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Nurses play an essential role in caring for patients with diffuse large b-cell lymphoma (DLBCL); learn more about the core elements of nursing practice in this PeerView video activity, featuring two leading oncology nurses who will focus on novel antibody and CAR-T cell therapies for the management of R/R DLBCL. Using a case-based format, the panelists will detail how antibodies and CAR-T therapy are now a part of the treatment toolkit and provide guidance on important considerations including: therapeutic sequencing, safety concerns, and counseling patients on appropriate dosing, treatment schedules, and premedication recommendations. Upon completion of this activity, participants should be better able to: Cite current clinical evidence supporting the integration of novel antibody and CAR-T cell therapies for the management of diffuse large B-cell lymphoma (DLBCL); Educate patients on safety, dosing, and treatment expectations associated with novel CD19, CD79, and CD3/CD20 targeting antibodies in the DLBCL setting; Counsel patients on the therapeutic role of cellular therapy in DLBCL, efficacy expectations, unique pre-therapy requirements, and adverse events such as CRS and neurotoxicity; and Manage practical considerations with novel antibodies and CAR-T therapy in DLBCL, including coordination of clinical visit or referral to specialized care, dosing considerations, and management of unique adverse events.

Spectrum | Deutsche Welle
Weekly roundup — Breathe it all in

Spectrum | Deutsche Welle

Play Episode Listen Later Sep 22, 2022 30:00


There's a chance (based on early data) that we'll be able to avoid COVID-19 infections altogether if 'mucosal vaccines' live up to their promise. Until then, though, get a good night's sleep (even if it's short).

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Sonia Glennie, ARNP, MSN, OCN, AGPCNP-BC - Moving Beyond Conventional Care for DLBCL: Oncology Nurse Leadership for the Effective and Safe Use of Innovative Antibody and Cellular Therapies

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Sep 22, 2022 35:02


Go online to PeerView.com/ZUH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Nurses play an essential role in caring for patients with diffuse large b-cell lymphoma (DLBCL); learn more about the core elements of nursing practice in this PeerView video activity, featuring two leading oncology nurses who will focus on novel antibody and CAR-T cell therapies for the management of R/R DLBCL. Using a case-based format, the panelists will detail how antibodies and CAR-T therapy are now a part of the treatment toolkit and provide guidance on important considerations including: therapeutic sequencing, safety concerns, and counseling patients on appropriate dosing, treatment schedules, and premedication recommendations. Upon completion of this activity, participants should be better able to: Cite current clinical evidence supporting the integration of novel antibody and CAR-T cell therapies for the management of diffuse large B-cell lymphoma (DLBCL); Educate patients on safety, dosing, and treatment expectations associated with novel CD19, CD79, and CD3/CD20 targeting antibodies in the DLBCL setting; Counsel patients on the therapeutic role of cellular therapy in DLBCL, efficacy expectations, unique pre-therapy requirements, and adverse events such as CRS and neurotoxicity; and Manage practical considerations with novel antibodies and CAR-T therapy in DLBCL, including coordination of clinical visit or referral to specialized care, dosing considerations, and management of unique adverse events.

Pregnancy Pearls Podcast
Antibodies in Pregnancy

Pregnancy Pearls Podcast

Play Episode Listen Later Sep 22, 2022 33:00


We all have antibodies circulating in our blood that help us fight off infections. But, if you're pregnant, some of those antibodies can cross the placenta and affect your unborn baby. This could lead to anemia of an unborn baby. Check out this episode to find out how we determine whether an antibody is significant or harmless. You'll also learn about how we determine if unborn babies are anemic, how these pregnancies are treated, and what you can do to prevent anemia in future pregnancies. This one is a laid back but educational chit chat. So, make sure you check this one out... especially if you're pregnant or planning to be pregnant. Download and listen now!See omnystudio.com/listener for privacy information.

PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
Sonia Glennie, ARNP, MSN, OCN, AGPCNP-BC - Moving Beyond Conventional Care for DLBCL: Oncology Nurse Leadership for the Effective and Safe Use of Innovative Antibody and Cellular Therapies

PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast

Play Episode Listen Later Sep 22, 2022 35:02


Go online to PeerView.com/ZUH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Nurses play an essential role in caring for patients with diffuse large b-cell lymphoma (DLBCL); learn more about the core elements of nursing practice in this PeerView video activity, featuring two leading oncology nurses who will focus on novel antibody and CAR-T cell therapies for the management of R/R DLBCL. Using a case-based format, the panelists will detail how antibodies and CAR-T therapy are now a part of the treatment toolkit and provide guidance on important considerations including: therapeutic sequencing, safety concerns, and counseling patients on appropriate dosing, treatment schedules, and premedication recommendations. Upon completion of this activity, participants should be better able to: Cite current clinical evidence supporting the integration of novel antibody and CAR-T cell therapies for the management of diffuse large B-cell lymphoma (DLBCL); Educate patients on safety, dosing, and treatment expectations associated with novel CD19, CD79, and CD3/CD20 targeting antibodies in the DLBCL setting; Counsel patients on the therapeutic role of cellular therapy in DLBCL, efficacy expectations, unique pre-therapy requirements, and adverse events such as CRS and neurotoxicity; and Manage practical considerations with novel antibodies and CAR-T therapy in DLBCL, including coordination of clinical visit or referral to specialized care, dosing considerations, and management of unique adverse events.

PeerView Clinical Pharmacology CME/CNE/CPE Video
Sonia Glennie, ARNP, MSN, OCN, AGPCNP-BC - Moving Beyond Conventional Care for DLBCL: Oncology Nurse Leadership for the Effective and Safe Use of Innovative Antibody and Cellular Therapies

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Sep 22, 2022 35:09


Go online to PeerView.com/ZUH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Nurses play an essential role in caring for patients with diffuse large b-cell lymphoma (DLBCL); learn more about the core elements of nursing practice in this PeerView video activity, featuring two leading oncology nurses who will focus on novel antibody and CAR-T cell therapies for the management of R/R DLBCL. Using a case-based format, the panelists will detail how antibodies and CAR-T therapy are now a part of the treatment toolkit and provide guidance on important considerations including: therapeutic sequencing, safety concerns, and counseling patients on appropriate dosing, treatment schedules, and premedication recommendations. Upon completion of this activity, participants should be better able to: Cite current clinical evidence supporting the integration of novel antibody and CAR-T cell therapies for the management of diffuse large B-cell lymphoma (DLBCL); Educate patients on safety, dosing, and treatment expectations associated with novel CD19, CD79, and CD3/CD20 targeting antibodies in the DLBCL setting; Counsel patients on the therapeutic role of cellular therapy in DLBCL, efficacy expectations, unique pre-therapy requirements, and adverse events such as CRS and neurotoxicity; and Manage practical considerations with novel antibodies and CAR-T therapy in DLBCL, including coordination of clinical visit or referral to specialized care, dosing considerations, and management of unique adverse events.

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Sonia Glennie, ARNP, MSN, OCN, AGPCNP-BC - Moving Beyond Conventional Care for DLBCL: Oncology Nurse Leadership for the Effective and Safe Use of Innovative Antibody and Cellular Therapies

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Sep 22, 2022 35:02


Go online to PeerView.com/ZUH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Nurses play an essential role in caring for patients with diffuse large b-cell lymphoma (DLBCL); learn more about the core elements of nursing practice in this PeerView video activity, featuring two leading oncology nurses who will focus on novel antibody and CAR-T cell therapies for the management of R/R DLBCL. Using a case-based format, the panelists will detail how antibodies and CAR-T therapy are now a part of the treatment toolkit and provide guidance on important considerations including: therapeutic sequencing, safety concerns, and counseling patients on appropriate dosing, treatment schedules, and premedication recommendations. Upon completion of this activity, participants should be better able to: Cite current clinical evidence supporting the integration of novel antibody and CAR-T cell therapies for the management of diffuse large B-cell lymphoma (DLBCL); Educate patients on safety, dosing, and treatment expectations associated with novel CD19, CD79, and CD3/CD20 targeting antibodies in the DLBCL setting; Counsel patients on the therapeutic role of cellular therapy in DLBCL, efficacy expectations, unique pre-therapy requirements, and adverse events such as CRS and neurotoxicity; and Manage practical considerations with novel antibodies and CAR-T therapy in DLBCL, including coordination of clinical visit or referral to specialized care, dosing considerations, and management of unique adverse events.

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Sonia Glennie, ARNP, MSN, OCN, AGPCNP-BC - Moving Beyond Conventional Care for DLBCL: Oncology Nurse Leadership for the Effective and Safe Use of Innovative Antibody and Cellular Therapies

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Sep 22, 2022 35:09


Go online to PeerView.com/ZUH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Nurses play an essential role in caring for patients with diffuse large b-cell lymphoma (DLBCL); learn more about the core elements of nursing practice in this PeerView video activity, featuring two leading oncology nurses who will focus on novel antibody and CAR-T cell therapies for the management of R/R DLBCL. Using a case-based format, the panelists will detail how antibodies and CAR-T therapy are now a part of the treatment toolkit and provide guidance on important considerations including: therapeutic sequencing, safety concerns, and counseling patients on appropriate dosing, treatment schedules, and premedication recommendations. Upon completion of this activity, participants should be better able to: Cite current clinical evidence supporting the integration of novel antibody and CAR-T cell therapies for the management of diffuse large B-cell lymphoma (DLBCL); Educate patients on safety, dosing, and treatment expectations associated with novel CD19, CD79, and CD3/CD20 targeting antibodies in the DLBCL setting; Counsel patients on the therapeutic role of cellular therapy in DLBCL, efficacy expectations, unique pre-therapy requirements, and adverse events such as CRS and neurotoxicity; and Manage practical considerations with novel antibodies and CAR-T therapy in DLBCL, including coordination of clinical visit or referral to specialized care, dosing considerations, and management of unique adverse events.

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Sonia Glennie, ARNP, MSN, OCN, AGPCNP-BC - Moving Beyond Conventional Care for DLBCL: Oncology Nurse Leadership for the Effective and Safe Use of Innovative Antibody and Cellular Therapies

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Sep 22, 2022 35:02


Go online to PeerView.com/ZUH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Nurses play an essential role in caring for patients with diffuse large b-cell lymphoma (DLBCL); learn more about the core elements of nursing practice in this PeerView video activity, featuring two leading oncology nurses who will focus on novel antibody and CAR-T cell therapies for the management of R/R DLBCL. Using a case-based format, the panelists will detail how antibodies and CAR-T therapy are now a part of the treatment toolkit and provide guidance on important considerations including: therapeutic sequencing, safety concerns, and counseling patients on appropriate dosing, treatment schedules, and premedication recommendations. Upon completion of this activity, participants should be better able to: Cite current clinical evidence supporting the integration of novel antibody and CAR-T cell therapies for the management of diffuse large B-cell lymphoma (DLBCL); Educate patients on safety, dosing, and treatment expectations associated with novel CD19, CD79, and CD3/CD20 targeting antibodies in the DLBCL setting; Counsel patients on the therapeutic role of cellular therapy in DLBCL, efficacy expectations, unique pre-therapy requirements, and adverse events such as CRS and neurotoxicity; and Manage practical considerations with novel antibodies and CAR-T therapy in DLBCL, including coordination of clinical visit or referral to specialized care, dosing considerations, and management of unique adverse events.

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Sonia Glennie, ARNP, MSN, OCN, AGPCNP-BC - Moving Beyond Conventional Care for DLBCL: Oncology Nurse Leadership for the Effective and Safe Use of Innovative Antibody and Cellular Therapies

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Sep 22, 2022 35:09


Go online to PeerView.com/ZUH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Nurses play an essential role in caring for patients with diffuse large b-cell lymphoma (DLBCL); learn more about the core elements of nursing practice in this PeerView video activity, featuring two leading oncology nurses who will focus on novel antibody and CAR-T cell therapies for the management of R/R DLBCL. Using a case-based format, the panelists will detail how antibodies and CAR-T therapy are now a part of the treatment toolkit and provide guidance on important considerations including: therapeutic sequencing, safety concerns, and counseling patients on appropriate dosing, treatment schedules, and premedication recommendations. Upon completion of this activity, participants should be better able to: Cite current clinical evidence supporting the integration of novel antibody and CAR-T cell therapies for the management of diffuse large B-cell lymphoma (DLBCL); Educate patients on safety, dosing, and treatment expectations associated with novel CD19, CD79, and CD3/CD20 targeting antibodies in the DLBCL setting; Counsel patients on the therapeutic role of cellular therapy in DLBCL, efficacy expectations, unique pre-therapy requirements, and adverse events such as CRS and neurotoxicity; and Manage practical considerations with novel antibodies and CAR-T therapy in DLBCL, including coordination of clinical visit or referral to specialized care, dosing considerations, and management of unique adverse events.

PaperPlayer biorxiv neuroscience
Combined DiI and antibody labeling reveals complex dysgenesis of hippocampal spine synapses in a mouse model of Fragile X Syndrome.

PaperPlayer biorxiv neuroscience

Play Episode Listen Later Sep 22, 2022


Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2022.09.20.508741v1?rss=1 Authors: Speranza, L., Filiz, K. D., Goebel, S., Perrone-Capano, C., Pulcrano, S., Volpicelli, F., Francesconi, A. Abstract: Structural, functional, and molecular alterations in excitatory spine synapses are a common hallmark of many neurodevelopmental disorders including intellectual disability and autism. Here, we describe an optimized methodology, based on combined use of DiI and immunofluorescence, for rapid and sensitive characterization of the structure and composition of spine synapses in native brain tissue. We successfully demonstrate the applicability of this approach by examining the properties of hippocampal spine synapses in juvenile Fmr1 KO mice, a mouse model of Fragile X Syndrome. We find that mutant mice display pervasive dysgenesis of spine synapses evidenced by an overabundance of both abnormally elongated thin spines and cup-shaped spines, in combination with reduced density of mushroom spines. We further find that mushroom spines expressing the actin-binding protein Synaptopodin - a marker for spine apparatus - are more prevalent in mutant mice. Previous work identified spines with Synaptopodin/spine apparatus as the locus of mGluR-LTD, which is abnormally elevated in Fmr1 KO mice. Altogether, our data suggest this enhancement may be linked to the preponderance of this subset of spines in the mutant. Overall, these findings demonstrate the sensitivity and versatility of the optimized methodology by uncovering a novel facet of spine dysgenesis in Fmr1 KO mice. Copy rights belong to original authors. Visit the link for more info Podcast created by PaperPlayer

Neurology Minute
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease in the Mountain West

Neurology Minute

Play Episode Listen Later Sep 20, 2022 2:02


Dr. Melissa Wright discusses her abstract, "MOGAD in the Mountain West: Epidemiology and Outcomes in Pediatric and Adult Patients at Two Large Academic Referral Centers". You can find Dr. Wright's abstract, along with all of our summer conference abstracts here: https://www.aan.com/MSA/Public/Events/Index/44 This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information.

American Education FM
EP. 367 - Education red-flags, the ”Up Your Antibodies” campaign, and jab outcomes.

American Education FM

Play Episode Listen Later Sep 19, 2022 59:58


Listener emails highlight nefarious education circumstances in two states in America, AstraZeneca starts it's "Up Your Antibodies" PSA campaign to push the jabs and monoclonal antibodies for the "immune-compromised," and current examples of jab outcomes and frames of mind. Canadian Generic Ivermectin:  https://healthworldcp.com/products/stromectol.html WhatsHerFace:  https://www.youtube.com/watch?v=HqXiJ37Yqwk

MIB Agents OsteoBites
Overcoming PD-1 Inhibitor Resistance with a Monoclonal Antibody to Secreted Frizzled-Related Protein 2 in Metastatic Osteosarcoma

MIB Agents OsteoBites

Play Episode Listen Later Sep 16, 2022 52:52


We would like to thank the sponsor of this episode, BTG Speciality Pharmaceuticals. BTG provides rescue medicines typically used in emergency rooms and intensive care units to treat patients for whom there are limited treatment options. They are dedicated to delivering quality medicines that make a real difference to patients and their families through the development, manufacture, and commercialization of pharmaceutical products. Their current portfolio of antidotes counteracts certain snake venoms and the toxicity associated with some heart and cancer medications. Their drug, Voraxaze, is for high-dose methotrexate toxicity. --- Dr. Nancy DeMore is a board-certified breast surgical oncologist and is the BMW endowed chair in cancer research at MUSC Health. Dr. DeMore obtained her medical degree from Chicago Medical School. She completed her residency at Boston University Medical Center, a cancer research fellowship at Harvard Medical School, and fellowship training at Memorial Sloan Kettering Cancer Center. Dr. DeMore practiced as a professor of surgery at the University of North Carolina-Chapel Hill for 13 years. --- What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨ EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter.

The New Wave Entrepreneur
EP239: New iOS Allows to Delete and Edit Sent Messages, Billionaire Gives Away His Company, Free 247 Online Tutoring For Californians & More  (Friday Headlines)

The New Wave Entrepreneur

Play Episode Listen Later Sep 16, 2022 28:00


The New Wave Podcast: Daily Conversations On Web3.0, Business, Psychology, Psychedelics & More. A Show For People Seeking Spiritual, Psychological And Financial Sovereignty. Hosted Bya Best-Selling Author, Speaker and Entrepreneur Daniel DiPiazza. Join Daniel in his home studio for a weekly recap of the weirdest and craziest headlines of the past week. ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ⌛Timestamps⌛(05:28) iOS now allows deletion and editing of sent texts (10:31) Billionaire gives away his company(15:12) Antibodies found in Israel can fight all strains of COVID (18:26) Free online tutoring for Californians (21:59) Malcolm X becomes first black honorary in the Nebraska Hall of Fame ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~

Design Lab with Bon Ku
EP 89: Designing Intellectual Antibodies | Seema Yasmin

Design Lab with Bon Ku

Play Episode Listen Later Sep 15, 2022 39:41


Can we design intellectual antibodies? How does misinformation spread like a virus? Why do our brains cling to biases? Dr. Seema Yasmin is an Emmy Award-winning journalist, Pulitzer prize finalist, medical doctor and Stanford and UCLA professor as well as a CEO coach working with Corporate Edge. Dr. Yasmin served as a disease detective in the Epidemic Intelligence Service at the CDC, as a science reporter for The Dallas Morning News and medical analyst for CNN. The author of five books, her reporting appears in The New York Times, Rolling Stone, WIRED, Scientific American, and on the BBC, NBC and other news networks. Dr. Yasmin's unique combination of expertise as a dually-trained physician and medical journalist have been called upon by the Vatican, the Presidential Commission for the Study of Bioethical Issues and the White House. Yasmin is director of the Stanford Health Communication Initiative, clinical assistant professor of medicine at Stanford University, and visiting professor of crisis communication at UCLA's Anderson School of Management. She trained in journalism at the University of Toronto and in medicine at the University of Cambridge. Her newest book, What the Fact?! is a navigation guide for teens (and adults!) on how to survive the murky worlds of misinformation and disinformation and become savvy consumers of information. Episode Mentions: Seema's Website: https://seemayasmin.com/ Website: Stanford Health Communication Initiative Seema's New Book: What the Fact!? (Book drops on Sept 20th, 2022) Article: Must-read books coming out in Sept 2022 Article: Doctors are spreading COVID disinformation. California needs to do something about it Follow Seema: Twitter | Insta | TikTok | LinkedIn Episode Website: https://mailchi.mp/designlabpod/seemayasmin More episode sources & links Sign-up for Design Lab Podcast's Newsletter Previous Episode Newsletters and Shownotes Follow @DesignLabPod on Twitter Instagram and LinkedIn Follow @BonKu on Twitter & Instagram Check out the Health Design Lab Production by Robert Pugliese Edit by Fernando Queiroz Cover Design by Eden Lew Theme song by Emmanuel Houston Indexed in the Library of Congress: ISSN 2833-2032

The Body of Evidence
083 - Botox / Boosters / Magic Mushrooms

The Body of Evidence

Play Episode Listen Later Sep 13, 2022 54:17


What does the body of evidence say on the topic of Botox injections? Plus: we address the confusion over bivalent COVID-19 booster shots, and we look at a trial of magic mushrooms for alcohol use disorder!   Block 1: (3:00) Botox: what it is and what botulism does to you   Block 2: (9:00) Botox: how Botox works on wrinkles, a comparison between formulations, what can go wrong, why repeated injections are needed, and the non-cosmetic uses of the botulinum toxin   Block 3: (23:08) Bivalent booster vaccines and the reactive, libertarian public health response   Block 4: (36:01) Magic mushrooms for alcohol use disorder     * Jingle by Jillian Correia of Roctavio Canada * Theme music: “Fall of the Ocean Queen“ by Joseph Hackl. * Assistant researcher: Nicholas Koziris   To contribute to The Body of Evidence, go to our Patreon page at: http://www.patreon.com/thebodyofevidence/.   To make a one-time donation to our show, you can now use PayPal! https://www.paypal.com/donate?hosted_button_id=9QZET78JZWCZE   Patrons get a bonus show on Patreon called “Digressions”! Check it out!     References:   1) Our episode on sunscreen: https://bodyofevidence.ca/019-sunscreen-and-the-mmr-vaccine   2) The cosmetic benefit of botulinum toxin: https://doi.org/10.1067/mjd.2002.121356   3) Differences between formulations: https://doi.org/10.1046/j.1524-4725.2003.29017.x   4) The FDA's black box warning for Botox: https://jamanetwork.com/journals/jama/article-abstract/184061   5) Antibody formation after Botox: https://doi.org/10.1002/mds.23254   6) Cochrane review of Botox for migraine: https://doi.org/10.1136/bmjopen-2018-027953   7) Cochrane review of Botox for cervical dystonia: https://doi.org/10.1002/14651858.CD003633.pub4   8) Botox for urgency urinary incontinence: https://www.nejm.org/doi/full/10.1056/nejmoa1208872#:~:text=In%20summary%2C%20we%20found%20that,improvements%20in%20quality%20of%20life   9) New clinical trial of psilocybin-assisted psychotherapy for alcohol use disorder: https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2795625     Music Credits:   The following music was used for this media project: Music: Main Theme (The Grand Score) by Alexander Nakarada Free download: https://filmmusic.io/song/4960-main-theme-the-grand-score License (CC BY 4.0): https://filmmusic.io/standard-license Artist website: https://www.serpentsoundstudios.com/  

WI Morning News
WI Morning News 091322 - Scientists Find COVID Antibodies That Make Boosters Unnecessary

WI Morning News

Play Episode Listen Later Sep 13, 2022 10:41


Scientists Find COVID Antibodies That Make Boosters Unnecessary with Meg and ChrisSee omnystudio.com/listener for privacy information.

Future Science Group
Tech Blast | Single domain antibodies

Future Science Group

Play Episode Listen Later Sep 13, 2022 16:20


In this Tech Blast episode, BioTechniques' Digital Editor, Annie Coulson, discusses single domain antibodies with ProSci's Andy Lee, Lead Scientist of the Single Domain Antibody Program, and David Eling, Director of Business Development. Andy and David describe what single domain antibodies (sdAbs) are, including their unique characteristics, such as their small size. They then go on to explore the applications of sdAbs, from increasing resolution in imaging studies, to developing antidotes for snake venom. Listen to this episode to get an overview of sdAbs, how they could be incorporated into your research and their link to llamas. Contents: Introductions: 00:00–01:25 What are single domain antibodies? 01:25–3:05 Applications of single domain antibodies: 03:05–05:05 Unique characteristics of sdAbs: 05:05–07:55 sdAbs for SARS-CoV-2: 07:55–08:35 sdAbs for therapeutics and diagnostics: 08:35–11:25 Unique applications, including biosensors and animal feed: 11:25–12:50 Working with researchers to develop sdAbs: 12:50–13:25 The future of sdAbs: 13:25–15:50 Closing remarks: 15:50–16:20

Because Jitsu Podcast
#124: The Crumbling Narrative

Because Jitsu Podcast

Play Episode Listen Later Sep 12, 2022 74:41


The connection between the public covid narrative and reality has been a strained one for a very long time. But, some recent news is adding more tension to that connection, bringing it closer to the point where it will finally fail. Significant wins for common sense versus the gaslit media stories have given us all a reason to give a "hell yeah" today. ----- This episode is made possible by: The Canadian Story podcast: https://www.thecanadianstory.com/ Take Back Alberta - TBA - : https://t.me/takebackalberta and BioPro+: https://bioproteintech.com/product/biopro-plus ----- Subscribe to the Social Disorder Substack to get all the links, extras and info for the podcast like the one you just listened to: https://thesocialdisorder.substack.com/

The Podcast by KevinMD
Antibodies are the future of cancer treatment

The Podcast by KevinMD

Play Episode Listen Later Sep 10, 2022 16:55


"Since President Nixon declared war on cancer in 1971, and despite some great victories and many losses, there continues to be a never-ending battle in this long-fought war that seems never-ending. The convergence of great intellect and resources of academia and industry, fueled by continued entrepreneurship and investment funding into the biotechnology sector, despite the many risks of failure and expense, is one that is obvious to yield the greatest rewards to both prosperity and health. Ultimately, targeted therapies will improve lifespans and quality of life for cancer patients." Eugene Chan is a health care executive. He shares his story and discusses his KevinMD article, "Cancer of the future: diagnosis, treatment, and impact on the health care system and patients." Did you enjoy today's episode? Rate and review the show so more audiences can find The Podcast by KevinMD. Subscribe on your favorite podcast app to get notified when a new episode comes out. Click here to earn 1.0 AMA PRA Category 1 CME for this episode. Also available in Category 1 CME bundles. Powered by CMEfy - a seamless way for busy clinician learners to discover Internet Point-of-Care Learning opportunities that reward AMA PRA Category 1 Credit(s)™. Learn more at about.cmefy.com/cme-info

Real Talk: Eosinophilic Diseases
Genetics and Eosinophilic Colitis (EOC)

Real Talk: Eosinophilic Diseases

Play Episode Listen Later Sep 9, 2022 30:39


Description: Co-hosts Ryan Piansky and Holly Knotowicz talk with guest Nicole Arva, MD, PhD, about genetics and eosinophilic colitis. Dr. Arva is a pediatric pathologist at Ann & Robert H. Lurie Children's Hospital of Chicago. She is also an Associate Professor in the Department of Pathology at Northwestern University Feinberg School of Medicine. She has been a part of more than 50 publications, many of which explore eosinophilic diseases, and recently co-authored a manuscript entitled “Genetics of Eosinophilic Colitis Revealed.” In this episode, Holly and Ryan discuss with Dr. Arva her recent and upcoming research. They cover the purposes of molecular testing and a new molecular study that concludes that EoC is a unique disease, with specific genetic characteristics that set it apart from other EGIDs, Crohn's disease, and IBD. Dr. Arva explains how that uniqueness was discovered, and what it means for therapeutic options for EoC. Listen in to learn about this innovative research. Disclaimer: The information provided in this podcast is designed to support, not replace the relationship that exists between listeners and their healthcare providers. Opinions, information, and recommendations shared in this podcast are not a substitute for medical advice. Decisions related to medical care should be made with your healthcare provider. Opinions and views of guests and co-hosts are their own.   Key Takeaways: [1:44] Holly shares the topic of this episode, genetics and eosinophilic colitis (EoC), and introduces today's guest, Dr. Nicole Arva. [1:51] Dr. Nicole Arva is a Pediatric Pathologist at Ann & Robert H. Lurie Children's Hospital of Chicago and an Associate Professor in the Department of Pathology at Northwestern University Feinberg School of Medicine. [2:37] Dr. Arva wanted to understand the mechanisms of diseases to be able to treat them more efficiently. She tells of her professional journey after medical school, studying cancer and leukemia cell lines. She continued her medical training in pathology, specializing in pediatric pathology. [3:15] Dr. Arva's work involves assessing laboratory slides from pediatric tissue samples to establish a diagnosis.  [4:05] Dr. Arva explains molecular testing. An increasing number of diseases are found to have genetic abnormalities. Molecular testing can help lead to an accurate diagnosis. Dr. Arva describes getting a tumor diagnosis from molecular testing showing specific chromosomal translocations in correlation with microscopic examination. [5:23] By performing molecular testing, we can discover gene alterations that can help guide the development of new therapies. Molecular testing can uncover genes that can be targeted. [5:51] Genetic analysis can also provide insight into how a disease develops and shed light on the pathways that are involved. [6:35] Dr. Arva describes EoC. EoC affects the large bowel. Eosinophils cause inflammation in the colon. Patients usually have abdominal pain, diarrhea, which can be bloody, and fluid in the abdominal cavity. Patients can become malnourished. They may develop a bowel obstruction or perforation. [7:25] Studies have been performed on Eosinophilic Gastrointestinal Disorders (EGIDs) and Inflammatory Bowel Disease (IBD). But EoC is a poorly understood condition. When Dr. Arva and her colleagues started their study, they didn't know whether EoC should be considered to be within the spectrum of EGIDs or as an IBD. [8:03] The research team was looking to determine where EoC belongs because that would affect the way patients would be treated. Although EoC is similar to other EGIDs because eosinophils drive the inflammation,, EoC has a lower incidence than EGIDs, more severe symptoms, and co-morbidities. [8:38] EoC is similar to IBDs in that it is an inflammation of the large bowel, but a different type of cell is predominantly involved in IBD (neutrophil) with some eosinophils present.  [9:38] The diagnosis of EoC is challenging. Other, more common conditions can cause colonic eosinophilic inflammation.  When pathologists encounter eosinophilia in the large bowel, they have to think of other medical conditions that can cause that. A diagnosis of EoC is established only after other causes of gastrointestinal eosinophilia have been ruled out. [10:14] IBD, intestinal parasites, autoimmune or connective tissue disorders, and vasculitis can all mimic EoC. Certain medicines can induce eosinophilia. Eosinophils are normally found in the large bowel. [10:51] Pathologists have to establish eosinophil count values for each segment of the large bowel to best evaluate colonic biopsy; everybody needs to follow the standards when diagnosing EoC. [11:42] Patients suspected to have EoC may undergo lab testing, imaging, and colonoscopy to reach a diagnosis. The findings may vary, depending on which section of the bowel wall is infiltrated by eosinophils. [13:02] A biopsy may reveal an increased number of eosinophils. All these test results have to be combined to reach a diagnosis of EoC. [13:27] The focus of the study was performing molecular testing that was very helpful in diagnosing EoC. They found that nearly 1,000 genes were differentially expressed in EoC compared to normal participants or Crohn's disease subjects.  [14:30]  They found differences in gene expression between EoC and other types of EGIDs, such as eosinophilic esophagitis or gastritis. [15:02] The main chemotactic factor in EoC seems to be CCL11 (Eotaxin-1). CCL11 is a molecule that attracts eosinophils in the tissue. In eosinophilic esophagitis or gastritis, the main chemotactic factor appears to be CCL26 (Eotaxin-3). All these findings support the idea that EoC is a distinct entity, which is different from other EGIDs and IBD. [15:37] EoC seems to be driven by a mechanism that does not involve an allergic inflammation. The therapeutic strategy may be much different now that we have a better understanding of EoC. [16:23] Eosinophilic esophagitis has been shown to run in families and it would be beneficial to test family members with a blood test, allergy testing, or endoscopy if they develop symptoms. As eosinophilic colitis has a different epigenetic mechanism, it is not clear that the same testing is needed for EoC patients or family members. [17:26] Besides endoscopies and colonoscopies, blood tests looking for high IgE levels, allergy testing, and CT can be useful in testing for various eosinophilic disorders. [21:07] Dr. Arva explains how many eosinophils are seen in a high-power field of a slide from a colon biopsy to diagnose EoC. They established a normal count of eosinophils for the segment of the colon and the abnormal count would be twice the normal count. [22:20] Now that a different pathogenic mechanism has been discovered for EoC than for EGIDs and IBD, new treatments can be explored or developed. We are just beginning the research. CLC protein (galectin-10) is upregulated in EoC and may be a target for treatment development. Antibodies may be effective for relieving EoC inflammation. [23:34] It is challenging to treat EoC because the newly-discovered pathogenic mechanism shows that EoC is unlikely to be allergic in nature, making elimination diets and steroid treatments ineffective. New therapies will be required. [24:05] All EGIDs can have a significant impact on quality of life. People with EoC can develop serious complications, such as dehydration, malnutrition, intestinal strictures, and bowel obstruction. [25:04] Dr. Arva considers the difficulties pathologists face in analyzing eosinophilic diseases. There are few patients with EoC. Dr. Arva describes additional challenges. [26:25] Dr. Arva looks ahead. Most of her research goes in the direction of pediatric gastroenterology. She is working with a clinical colleague, Dr. Josh Weschler, to analyze the role of mast cells in EGIDs. They are finding that eosinophils are not the only offenders in EGIDs and are looking to establish a cohort of EGID patients to study. [27:43] Holly thanks Dr. Arva for taking the time to talk with us today. [27:51] Dr. Arva says we are just at the beginning of understanding the etiology of EoC. This study had a small sample size and the results will have to be validated with larger cohorts of patients. The analyses were performed on whole biopsies that contained all types of cells. Future studies using single-cell preparations will be important. [28:55] Ryan invites listeners to look at apfed.org/eoc to learn more about EoC. Ryan also encourages you to connect with the APFED online community at apfed.org/connections. [29:25] Dr. Arva thanks Ryan and Holly for having her on the podcast. She is grateful for the opportunity to research EGIDs and benefit patients suffering from these conditions.   Mentioned in This Episode: American Partnership for Eosinophilic Disorders (APFED) APFED on YouTube, Twitter, Facebook, Pinterest, Instagram Nicole Arva, MD, PhD Ann & Robert H. Lurie Children's Hospital of Chicago® Department of Pathology at Northwestern University “Genetics of Eosinophilic Colitis Revealed” Apfed.org/eoc APFED Eos Connections Online Community Real Talk: Eosinophilic Diseases Podcast APFED Podcast Episode Featuring Holly Knotowicz Tetsuo Shoda Joshua B Wechsler   This episode is brought to you thanks to the support of our Education Partners Abbott, Bristol Myers Squibb, GlaxoSmithKline, Mead Johnson Nutrition, Sanofi, and Regeneron.   Tweetables: “I have always wanted to better understand the mechanisms of diseases because I considered that if we know how an illness occurs, we can treat that entity more efficiently.” — Dr. Nicole Arva “As testing increases, more and more diseases are found to have recurrent genetic abnormalities. … Molecular testing can help the pathologist to render the correct diagnosis.” — Dr. Nicole Arva “There are similarities and dissimilarities between EoC and other EGIDs and IBD.” — Dr. Nicole Arva “Findings support the idea that EoC … seems to be driven by a mechanism that does not involve an allergic inflammation.” — Dr. Nicole Arva

Blood Podcast
Rest alleviates T-cell exhaustion by bispecific antibodies, exercise vs desmopressin in mild hemophilia A, and targeting MDM2 to enhance antileukemia immunity after transplant

Blood Podcast

Play Episode Listen Later Sep 8, 2022 18:15


Information Morning Fredericton from CBC Radio New Brunswick (Highlights)

Dr. Peter Lin talk​s​ about Covid infection rates across Canada​, ​and how a lack of testing data may be easing people into a false sense of security.

Endpoints
Dr. Silvia Pozzi on the State of Antibody Therapies for ALS

Endpoints

Play Episode Listen Later Sep 6, 2022 15:43


Antibodies are an essential part of our bodies' defenses against diseases. They are specialized proteins that attack and kill foreign invaders like infectious bacteria and viruses. Antibodies are normally naturally produced by our immune system in response to an infection. However, in recent years, scientists have learned to produce antibodies in a lab to treat a variety of diseases.  Several Antibody treatments have been investigated in ALS, including tegoprubart, which was invented by ALS TDI and recently successfully completed a phase 2a clinical trial. Dr. Silvia Pozzi is Assistant Professor at the Université Laval's Brain Research Center in Quebec City specializing in ALS Research. She recently was an author on a paper reviewing the current state of antibody therapies for ALS.  She joined us on Endpoints to discuss the current outlook for these therapies in the ALS space – as well as what the future might hold for these treatments.Support the show: https://www.als.net/donate/See omnystudio.com/listener for privacy information.

Hematologic Oncology Update
Data + Perspectives: Investigators Discuss the Current and Future Roles of Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies in the Care of Patients with Hematologic Cancers

Hematologic Oncology Update

Play Episode Listen Later Sep 1, 2022 97:32


Proceedings from an educational event held in partnership with the 2022 Pan Pacific Lymphoma Conference, featuring perspectives from Drs Ajai Chari, Ian Flinn, Nikhil Munshi and Laurie Sehn, moderated by Dr Neil Love.

Research To Practice | Oncology Videos
Hematologic Cancers | Data + Perspectives: Investigators Discuss the Current and Future Roles of Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies in the Care of Patients with Hematologic Cancers

Research To Practice | Oncology Videos

Play Episode Listen Later Sep 1, 2022 97:29


Featuring perspectives from Drs Ajai Chari, Ian Flinn, Nikhil Munshi and Laurie Sehn, including the following topics: Part 1: Case Presentations and Clinical Decision-Making (0:00) Case: A man in his early 70s with diffuse large B-cell lymphoma (DLBCL) arising from follicular lymphoma — Ian W Flinn, MD, PhD (3:46) Case: A man in his late 50s with nongerminal center B-cell-like subtype DLBCL — Laurie H Sehn, MD, MPH (15:57) Case: CAR-T therapy during the pandemic — Nikhil C Munshi, MD (22:16) Case: Anti-BCMC bispecific in triple-class and penta-drug refractory disease — Ajai Chari, MD (33:54) CAR-T therapy for non-Hodgkin lymphoma — Dr Flinn (37:09) Bispecifics for non-Hodgkin lymphoma — Dr Sehn (51:48) CAR-T therapy for multiple myeloma — Dr Munshi (1:13:23) Bispecifics for multiple myeloma — Dr Chari (1:26:14) CME information and select publications

Metabolic Moments - Live better longer
Metabolic Moments: More Cancer Success – Have Researchers Created Cancer Antibodies?

Metabolic Moments - Live better longer

Play Episode Listen Later Aug 31, 2022 2:36


The success of modern vaccines has encouraged scientists to try its mRNA model. Want to know how the messenger RNA interacts with muscle cells? Take a listen today!

ACR on Air
36. Hot Topics – Spring & Summer 2022 Edition

ACR on Air

Play Episode Listen Later Aug 30, 2022 30:22


This week's episode is another installment of our popular “Hot Topics” series, where we discuss “must read” studies recently published in one of ACR's three peer-reviewed journals. Joining us is Dr. Vicki Shanmugam. Not just our guest today, but also the host of a new ACR podcast series, “ACR Journals on Air” scheduled to launch later this summer. Today, we'll hear what we can expect from her new podcast, and we'll talk about some of her favorite studies in the ACR's journals right now. Enjoy! 

The Medbullets Step 1 Podcast
Immunology | Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)

The Medbullets Step 1 Podcast

Play Episode Listen Later Aug 29, 2022 6:29


In this episode, we review the high-yield topic of Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) from the Immunology section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbulletsIn --- Send in a voice message: https://anchor.fm/medbulletsstep1/message

This Week in Virology
TWiV 930: Clinical update with Dr. Daniel Griffin

This Week in Virology

Play Episode Listen Later Aug 27, 2022 48:18 Very Popular


In his weekly clinical update Dr. Griffin discusses antibody response against nonpoliovirus enteroviruses, clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain, object and surface contamination with monkeypox virus, monkeypox virus infection in humans across 16 countries, clinical characteristics of ambulatory and hospitalized patients with monkeypox virus infection, compassionate use of Tecovirimat for the treatment of monkeypox infection, monitoring of Pfizer-BioNTech vaccine among children, Pfizer and BioNTech announce updated vaccine data supporting efficacy in children, direct capture of neutralized RBD enables rapid point-of-care assessment of SARS-CoV-2 neutralizing antibody titer, Pfizer and BioNTech submit application for bivalent vaccine, and Oral Nirmatrelvir and Ritonavir in non-hospitalized vaccinated patients with COVID-19. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Antibody response against nonpoliovirus enteroviruses (ASM) Clinical presentation of Monkeypox cases in Spain (The Lancet) Object and surface contamination with Monkeypox virus infection (CDC) Environmental persistence of Monkeypox virus (Emerg Inf Dis) Monkeypox virus infection across 16 countries (NEJM) Clinical characteristics of hospitalization patients with Monkeypox (CMI) Usage of Tecovirimat for treatment of Monkeypox infection (JAMA) PAXLOVID patient eligibility screening checklist (FDA) Remdesivir fact sheet for providers (Veklury)  Bebtelovimab fact sheet for providers (FDA) Monitoring of Pfizer-BioNTech vaccine among children (CDC) Pfizer and BioNTech announce updated vaccine data (Pfizer) Capture of RBD enables point of care assessment (Science Direct) Pfizer and BioNTech submit application for bivalent vaccine (Pfizer) PAXLOVID in non-hospitalized vaccinated patients  Contribute to Floating Doctors fundraiser at PWB Dr. Griffin's treatment guide (pdf) Letters read on TWiV 930 Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Beth Faiman, PhD, RN, MSN, ANP-BC, AOCN, FAAN - Reaching the Next Level of Myeloma Patient Care: Oncology Nurse Guidance on Antibody Therapy and Novel Mechanisms of Action

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Aug 25, 2022 35:12


Go online to PeerView.com/BRG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This activity provides a model for “next-level” nursing practice in multiple myeloma (MM) by linking current evidence supporting the use of innovative antibody, CAR-T, and targeted treatment platforms with case-based teaching examples designed to cover the spectrum of myeloma care. Furthermore, experts give guidance on nursing principles, including educational and counseling strategies, patient monitoring, and adverse event management, that can be used to modernize care and facilitate the integration of effective, innovative therapies into the management of newly diagnosed myeloma, the early relapse setting, or heavily pretreated disease are described. Upon completion of this activity, participants should be better able to: Summarize updated evidence and current guidelines supporting treatment roles of novel therapeutics in newly diagnosed and relapsed MM care, including novel monoclonal antibodies, antibody–drug conjugates, targeted agents, and CAR-T therapy; Manage the unique spectrum of adverse events associated with novel therapeutics used to treat MM, including events such as infection, infusion reactions, ocular toxicity, GI events, CRS, or neurotoxicity; Counsel patients about efficacy and safety expectations and potential toxicities associated with novel therapies across the MM spectrum, including in patients receiving antibody-based regimens, targeted agents, or cellular therapy.

PeerView Clinical Pharmacology CME/CNE/CPE Video
Beth Faiman, PhD, RN, MSN, ANP-BC, AOCN, FAAN - Reaching the Next Level of Myeloma Patient Care: Oncology Nurse Guidance on Antibody Therapy and Novel Mechanisms of Action

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Aug 25, 2022 35:13


Go online to PeerView.com/BRG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This activity provides a model for “next-level” nursing practice in multiple myeloma (MM) by linking current evidence supporting the use of innovative antibody, CAR-T, and targeted treatment platforms with case-based teaching examples designed to cover the spectrum of myeloma care. Furthermore, experts give guidance on nursing principles, including educational and counseling strategies, patient monitoring, and adverse event management, that can be used to modernize care and facilitate the integration of effective, innovative therapies into the management of newly diagnosed myeloma, the early relapse setting, or heavily pretreated disease are described. Upon completion of this activity, participants should be better able to: Summarize updated evidence and current guidelines supporting treatment roles of novel therapeutics in newly diagnosed and relapsed MM care, including novel monoclonal antibodies, antibody–drug conjugates, targeted agents, and CAR-T therapy; Manage the unique spectrum of adverse events associated with novel therapeutics used to treat MM, including events such as infection, infusion reactions, ocular toxicity, GI events, CRS, or neurotoxicity; Counsel patients about efficacy and safety expectations and potential toxicities associated with novel therapies across the MM spectrum, including in patients receiving antibody-based regimens, targeted agents, or cellular therapy.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Beth Faiman, PhD, RN, MSN, ANP-BC, AOCN, FAAN - Reaching the Next Level of Myeloma Patient Care: Oncology Nurse Guidance on Antibody Therapy and Novel Mechanisms of Action

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Aug 25, 2022 35:12


Go online to PeerView.com/BRG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This activity provides a model for “next-level” nursing practice in multiple myeloma (MM) by linking current evidence supporting the use of innovative antibody, CAR-T, and targeted treatment platforms with case-based teaching examples designed to cover the spectrum of myeloma care. Furthermore, experts give guidance on nursing principles, including educational and counseling strategies, patient monitoring, and adverse event management, that can be used to modernize care and facilitate the integration of effective, innovative therapies into the management of newly diagnosed myeloma, the early relapse setting, or heavily pretreated disease are described. Upon completion of this activity, participants should be better able to: Summarize updated evidence and current guidelines supporting treatment roles of novel therapeutics in newly diagnosed and relapsed MM care, including novel monoclonal antibodies, antibody–drug conjugates, targeted agents, and CAR-T therapy; Manage the unique spectrum of adverse events associated with novel therapeutics used to treat MM, including events such as infection, infusion reactions, ocular toxicity, GI events, CRS, or neurotoxicity; Counsel patients about efficacy and safety expectations and potential toxicities associated with novel therapies across the MM spectrum, including in patients receiving antibody-based regimens, targeted agents, or cellular therapy.

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Beth Faiman, PhD, RN, MSN, ANP-BC, AOCN, FAAN - Reaching the Next Level of Myeloma Patient Care: Oncology Nurse Guidance on Antibody Therapy and Novel Mechanisms of Action

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Aug 25, 2022 35:13


Go online to PeerView.com/BRG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This activity provides a model for “next-level” nursing practice in multiple myeloma (MM) by linking current evidence supporting the use of innovative antibody, CAR-T, and targeted treatment platforms with case-based teaching examples designed to cover the spectrum of myeloma care. Furthermore, experts give guidance on nursing principles, including educational and counseling strategies, patient monitoring, and adverse event management, that can be used to modernize care and facilitate the integration of effective, innovative therapies into the management of newly diagnosed myeloma, the early relapse setting, or heavily pretreated disease are described. Upon completion of this activity, participants should be better able to: Summarize updated evidence and current guidelines supporting treatment roles of novel therapeutics in newly diagnosed and relapsed MM care, including novel monoclonal antibodies, antibody–drug conjugates, targeted agents, and CAR-T therapy; Manage the unique spectrum of adverse events associated with novel therapeutics used to treat MM, including events such as infection, infusion reactions, ocular toxicity, GI events, CRS, or neurotoxicity; Counsel patients about efficacy and safety expectations and potential toxicities associated with novel therapies across the MM spectrum, including in patients receiving antibody-based regimens, targeted agents, or cellular therapy.

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Beth Faiman, PhD, RN, MSN, ANP-BC, AOCN, FAAN - Reaching the Next Level of Myeloma Patient Care: Oncology Nurse Guidance on Antibody Therapy and Novel Mechanisms of Action

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Aug 25, 2022 35:13


Go online to PeerView.com/BRG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This activity provides a model for “next-level” nursing practice in multiple myeloma (MM) by linking current evidence supporting the use of innovative antibody, CAR-T, and targeted treatment platforms with case-based teaching examples designed to cover the spectrum of myeloma care. Furthermore, experts give guidance on nursing principles, including educational and counseling strategies, patient monitoring, and adverse event management, that can be used to modernize care and facilitate the integration of effective, innovative therapies into the management of newly diagnosed myeloma, the early relapse setting, or heavily pretreated disease are described. Upon completion of this activity, participants should be better able to: Summarize updated evidence and current guidelines supporting treatment roles of novel therapeutics in newly diagnosed and relapsed MM care, including novel monoclonal antibodies, antibody–drug conjugates, targeted agents, and CAR-T therapy; Manage the unique spectrum of adverse events associated with novel therapeutics used to treat MM, including events such as infection, infusion reactions, ocular toxicity, GI events, CRS, or neurotoxicity; Counsel patients about efficacy and safety expectations and potential toxicities associated with novel therapies across the MM spectrum, including in patients receiving antibody-based regimens, targeted agents, or cellular therapy.

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Beth Faiman, PhD, RN, MSN, ANP-BC, AOCN, FAAN - Reaching the Next Level of Myeloma Patient Care: Oncology Nurse Guidance on Antibody Therapy and Novel Mechanisms of Action

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Aug 25, 2022 35:12


Go online to PeerView.com/BRG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This activity provides a model for “next-level” nursing practice in multiple myeloma (MM) by linking current evidence supporting the use of innovative antibody, CAR-T, and targeted treatment platforms with case-based teaching examples designed to cover the spectrum of myeloma care. Furthermore, experts give guidance on nursing principles, including educational and counseling strategies, patient monitoring, and adverse event management, that can be used to modernize care and facilitate the integration of effective, innovative therapies into the management of newly diagnosed myeloma, the early relapse setting, or heavily pretreated disease are described. Upon completion of this activity, participants should be better able to: Summarize updated evidence and current guidelines supporting treatment roles of novel therapeutics in newly diagnosed and relapsed MM care, including novel monoclonal antibodies, antibody–drug conjugates, targeted agents, and CAR-T therapy; Manage the unique spectrum of adverse events associated with novel therapeutics used to treat MM, including events such as infection, infusion reactions, ocular toxicity, GI events, CRS, or neurotoxicity; Counsel patients about efficacy and safety expectations and potential toxicities associated with novel therapies across the MM spectrum, including in patients receiving antibody-based regimens, targeted agents, or cellular therapy.

Empowered Patient Podcast
Using Antibody Therapeutics to Block Allergic Reactions with Dr. Jessica Grossman IgGenix

Empowered Patient Podcast

Play Episode Listen Later Aug 22, 2022 17:32


Dr. Jessica Grossman is the CEO of an early stage biotech, IgGenix, the world leader in discovering and characterizing IgE antibodies which have been identified as the cause of allergies.  With an initial focus on peanut allergy, IgGenix is developing a plan to use a subcutaneous injection to block specific allergic reactions immediately. Jessica explains, "At IgGenix, what we do is start with whole blood donations from allergic donors. And we take that blood and isolate out the single B cells that are making the IgE antibodies. We get those IgE antibodies, and we transform them into an IgG antibody that's actually protective. And I'll use again, peanut as an example. That's our lead program, which we're the furthest ahead. We have done some pre-clinical work, some animal studies, which look remarkably promising, and I'm excited about it. But what we envision our therapy looking like is an antibody therapeutic that would be given to an individual, and the antibody would immediately protect them from any accidental exposure." "So we isolate these very rare B cells that produce IgE antibodies, and they're about 0.05% of the circulating blood cells. Because the IgE antibodies are so rare, they're also extremely potent, meaning they have a very high affinity. And when you are allergic, they seek out the food that you're allergic to and cause this immediate reaction. What we're doing is taking those very potent IgE antibodies, converting them to IgG antibodies to act as blockers." #IgGenix #FoodAllergyResearch #AllergicDisease #BCells #AntibodyTherapeutics #AirborneAllergies #EnvironmentalAllergies #SustainableInnovation #WomenInSTEM #Biotech IgGenix.com Download the transcript here

Empowered Patient Podcast
Using Antibody Therapeutics to Block Allergic Reactions with Dr. Jessica Grossman IgGenix TRANSCRIPT

Empowered Patient Podcast

Play Episode Listen Later Aug 22, 2022


Dr. Jessica Grossman is the CEO of an early stage biotech, IgGenix, the world leader in discovering and characterizing IgE antibodies which have been identified as the cause of allergies.  With an initial focus on peanut allergy, IgGenix is developing a plan to use a subcutaneous injection to block specific allergic reactions immediately. Jessica explains, "At IgGenix, what we do is start with whole blood donations from allergic donors. And we take that blood and isolate out the single B cells that are making the IgE antibodies. We get those IgE antibodies, and we transform them into an IgG antibody that's actually protective. And I'll use again, peanut as an example. That's our lead program, which we're the furthest ahead. We have done some pre-clinical work, some animal studies, which look remarkably promising, and I'm excited about it. But what we envision our therapy looking like is an antibody therapeutic that would be given to an individual, and the antibody would immediately protect them from any accidental exposure." "So we isolate these very rare B cells that produce IgE antibodies, and they're about 0.05% of the circulating blood cells. Because the IgE antibodies are so rare, they're also extremely potent, meaning they have a very high affinity. And when you are allergic, they seek out the food that you're allergic to and cause this immediate reaction. What we're doing is taking those very potent IgE antibodies, converting them to IgG antibodies to act as blockers." #IgGenix #FoodAllergyResearch #AllergicDisease #BCells #AntibodyTherapeutics #AirborneAllergies #EnvironmentalAllergies #SustainableInnovation #WomenInSTEM #Biotech IgGenix.com Listen to the podcast here

Talking Biotech Podcast
Creating Targeted Antibodies in Single Cells

Talking Biotech Podcast

Play Episode Listen Later Aug 20, 2022 52:03 Very Popular


Immunotherapies represent a powerful suite of treatments that co-opt the immune system to target deleterious cellular conditions.  They have been effective with a series of cancers and other disorders. The problem is that development of new antibodies can be challenging for several technical reasons, but also because no two people are alike. Dr. Liang Schweizer of HiFiBio describes how her company is using single-cells and microfluidics to identify new antibodies that may be mobilized against discrete cellular targets, as well as what they have learned about heterogeneity between patients and how to identify specific biomarkers that could guide application of the most effective treatments. 

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
Robert Z. Orlowski, MD, PhD - Building Real-World Bridges Between Clinicians and Patients With Myeloma: Guidance on Innovative Antibody Options

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast

Play Episode Listen Later Aug 11, 2022 67:16


Go online to PeerView.com/JPJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The modern management of multiple myeloma (MM) continues to be transformed by the emergence and further integration of different antibody-based approaches into patient management. How can professionals exploit these advances while using the principles of shared decision-making when caring for patients? In this activity, two hematologist-oncologists and a patient advocate explore these themes through a case-based discussion of novel antibody platforms in a range of MM treatment settings. Learners can expect insights on the safety and efficacy evidence supporting the use of antibody-based therapies in newly diagnosed and relapsed MM, along with practical guidance for safe delivery of care, and strategies for engaging with patients when developing treatment plans that include antibody components. Upon completion of this activity, participants should be better able to: Summarize current evidence and guideline recommendations surrounding the use of novel antibody platforms in multiple myeloma (MM); Integrate established and emerging antibody options, including monoclonal and bispecific antibodies, into treatment plans for patients with MM based on guideline recommendations and the latest clinical data; Address practical aspects of antibody therapy in MM, including unique safety considerations and effective sequential treatment; and Counsel patients with MM on dosing, safety, drug delivery, and therapeutic expectations with novel antibodies when engaging in shared decision-making discussions.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Robert Z. Orlowski, MD, PhD - Building Real-World Bridges Between Clinicians and Patients With Myeloma: Guidance on Innovative Antibody Options

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Aug 11, 2022 67:07


Go online to PeerView.com/JPJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The modern management of multiple myeloma (MM) continues to be transformed by the emergence and further integration of different antibody-based approaches into patient management. How can professionals exploit these advances while using the principles of shared decision-making when caring for patients? In this activity, two hematologist-oncologists and a patient advocate explore these themes through a case-based discussion of novel antibody platforms in a range of MM treatment settings. Learners can expect insights on the safety and efficacy evidence supporting the use of antibody-based therapies in newly diagnosed and relapsed MM, along with practical guidance for safe delivery of care, and strategies for engaging with patients when developing treatment plans that include antibody components. Upon completion of this activity, participants should be better able to: Summarize current evidence and guideline recommendations surrounding the use of novel antibody platforms in multiple myeloma (MM); Integrate established and emerging antibody options, including monoclonal and bispecific antibodies, into treatment plans for patients with MM based on guideline recommendations and the latest clinical data; Address practical aspects of antibody therapy in MM, including unique safety considerations and effective sequential treatment; and Counsel patients with MM on dosing, safety, drug delivery, and therapeutic expectations with novel antibodies when engaging in shared decision-making discussions.

The Thyroidless Life
Thyroid Q&A Part TWO! Hashimoto's, Graves, and High Antibodies

The Thyroidless Life

Play Episode Listen Later Aug 10, 2022 53:50


Our first thyroid q&a was so popular I decided to come back and answer more of YOUR questions! Listen in as we go deep and focus on thyroid autoimmunity issues (like Hashimoto's and Grave's). Questions answered in today's episode: My tpo antibodies are a 10. When is it considered to be hashimotos? if you forget to take your medication do you take it once you've realized you forgotten or take a double dose the next day? I have Hashimoto's with my blood results showing TPO antibodies of 358IU/ml and Thyroid Globulin antibodies of 425 IU/ml do these levels indicate cancer ? My TSH was high, and I have high antibodies, where do I start? Want to take your health to the next level? Here's where to start: Join my Thyroid Inner Circle Membership: thyroidinnercircle.com Order your own tests, whether it's bloodwork or something deeper like cortisol testing you can check out options here: Testing Get your free Optimal Thyroid Labs ebook: www.drrebeccawarren.com Have you had a thyroidectomy? Healing After Thyroidectomy Facebook Group Make sure to subscribe, and leave a review if you enjoyed today's episode! Disclaimer: This podcast is for information purposes only. Statements and views expressed on this podcast are not medical advice. This podcast including Drs.Warren disclaim responsibility from any possible adverse effects from the use of information contained herein. Opinions of guests are their own, and this podcast does not accept responsibility of statements made by guests. This podcast does not make any representations or warranties about guests qualifications or credibility. Individuals on this podcast may have a direct or non-direct interest in products or services referred to herein. If you think you have a medical problem, consult a licensed physician.

Lavender Mafia
Episode 43. “Getting Sick,” Or: “My Antibody, My Choice”

Lavender Mafia

Play Episode Listen Later Aug 6, 2022 84:02


This week Jess & Jack have a conversation about getting sick and, relatedly, explain our unintentional summer hiatus. We talk about our experiences getting COVID and battling virus-shaming. We also talk about monkeypox: what it is, how it seems to spread (and how it doesn't), similarities with both COVID and HIV, and the harms of talking about it as a “gay disease.” Visit linktr.ee/lavmafia for our IG, Twitter, Facebook community page, Discord, and Patreon, and go to lavmafia.com for merch!

COVID NoiseFilter - Doctors Explain the Latest on COVID-19
Ep. 600 - Drug Use in Prisons, Stress from Teaching, and COVID Vaccine Antibodies in Breast Milk

COVID NoiseFilter - Doctors Explain the Latest on COVID-19

Play Episode Listen Later Aug 5, 2022 10:00


Today, in episode 600, our expert Infectious Disease Doctor and Community Health Specialist discuss what you need to know about Public Health. We talk about drug use and overdoses in prisons, as well as how teaching is twice as stressful as other jobs, and how COVID vaccine antibodies in breast milk provide protection for infants. As always, join us for all the Public Health information you need, explained clearly by our health experts. Website: NoiseFilter - Complex health topics explained simply (noisefiltershow.com) Animations: NoiseFilter - YouTube Instagram: NoiseFilter (@noisefiltershow) • Instagram photos and videos Facebook: NoiseFilter Show | Facebook TikTok: https://www.tiktok.com/@noisefiltershow --- Send in a voice message: https://anchor.fm/noisefilter/message

The Cabral Concept
2339: Addison's & Diet, Kids and Supplements, Ectopic Heartbeats, Thyroid Antibodies, Recurring UTI's & Antibiotics, CBO Protocol & Eating Baked Goods (HouseCall)

The Cabral Concept

Play Episode Listen Later Jul 2, 2022 17:51 Very Popular


Welcome back to our weekend Cabral HouseCall shows! This is where we answer our community's wellness, weight loss, and anti-aging questions to help people get back on track! Check out today's questions:    Michael: Hi Stephen, hope you are keeping well. I'm an Addison's disease patient since July 2021 after a long few months trying to get a diagnosis - brain fog, weight loss, anxiety and panic attacks, adrenal crisis and OCD. I'm hearing a lot about different diets for autoimmune diseases and wondering your thoughts on cutting out gluten sugar and dairy to help. Currently taking hydro and fludrocortisone daily. Also in terms of vitamins what should I be taking daily just need some help getting my life back on track. Also I've had covid twice which def didn't help with addisons. Recently came across your podcast on adrenal fatigue and heard you have addisons as well. The thought of being on these heavy meds for life is kind of scary. I had all the symptoms you had and would love your opinion. Thanks Michael   Rachel: Hi there, Just wondering if you could do a podcast on your recommendations for children and supplements. I'd like to find out if it's necessary to provide children with Multivitamins and/or what supplements you suggest they take in conjunction with a balanced diet. Thank you.   Nicole: Hi Dr. Cabral. I have a question about my ectopic heartbeats. I've been battling chronic fatigue, stress, and gut issues for a few yrs now after having tragedy after tragedy in my family happen. Anyway I did do the oat test and HTMA as well as food sensitivity test and have a plan going forward to heal and seal my gut. However one very mysterious symptom I've been having ( out of a few actually) is that I get ectopic heartbeats all the time! Not just a few but hundreds a day. I did a heart ultrasound as well as 24 hr heart monitor and they found nearly 2500 pvc and pacs in a 24 hour period. These tend to happen during early morning and in the late afternoon into the evenings. They have gone away for weeks at a time entirely only to return once again for weeks- months. My cardiologist says they are benign and that its just anxiety. Wjat are your thoughts. I don't feel like I'm an anxious person although I do know with my ongoing health challenges and emotional stresses in the past this could have played a role to some degree. My thyroid panel is optimal at 30mg armour thyroid no no more antibodies present. Any help or advice would be greatly appreciated.   Sarah: Is it possible to completely get rid of thyroid antibodies? Mine has hovered around 300 for years and deciding if damage is done and should just go on thyroid med instead of chasing full reversal! Thankful for people like you putting in the time to help the world!   Courtney: Hello! Your story resonated with me as my 5 year old daughter has been on a daily 6ml antibiotic the last 2 years for recurring UTI's due to holding and reflux to the kidneys. Doctors believe she will grow out of it. I'm very concerned that the daily nitrofurantoin is ruining her gut flora and what this will mean for her future health. Even with the daily antibiotic she will have a UTI once every 3 months and will be on a full 10 day course of another antibiotic (keflex or Bactrum). She will be starting biofeedback when she is 6 (October). We give her a daily probiotic: Jarrow YumYum dophilius. What more can we do to help her break this cycle, get her off a daily antibiotic and get her gut health back? Thank you so much! Courtney   Rita: Hi! I've attempted the CBO protocol twice but can never seem to follow through properly all the way to 12 weeks. The problem is that I own a bakery and am always tasting our products for quality a few times a month, especially when we're creating new flavors. My bakery business truly brings me and my customers joy and fulfillment, so quitting that is currently not an option. I've taken the food sensitivity test and am highly sensitive to gluten, dairy and eggs. I don't need to have entire servings of our pastries but I'm wondering if this will affect the effectiveness of the CBO protocol during and after the process. I know I desperately need to rebalance my gut but don't know how to balance this with my livelihood. Please help! Thank you so much.   Thank you for tuning into today's Cabral HouseCall and be sure to check back tomorrow where we answer more of our community's questions!      - - - Show Notes and Resources: StephenCabral.com/2339 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!